Research > ETFs > ETF / ETP Commentary > 

For the Brave, Some Chinese Stocks Are Undervalued

  • Related Symbols
  • PGJ
Perhaps the most obvious lesson investors are learning this year with regards to emerging markets equities is that in China, regulation still looms large.Down 27% year-to-date, the Invesco Golden Dragon China ETF (PGJ B-) underscores the point that investing in Chinese stocks in 2021, particularly growth fare, is risky business. However, PGJ, which follows the NASDAQ Golden Dragon China Index, may be a source of opportunity for risk-tolerant investors going forward.Amid a bloodletting that’s seen shares of previously beloved Chinese internet names, including Alibaba (NYSE:BABA) and JD.com (NASDAQ:JD), tumble at the hands of Beijing’s regulatory crackdown, some analysts now believe that there’s some value to be had in this once high-flying group. That sentiment extends to several PGJ components.“Considering the series of recent regulatory actions from the Chinese government, we don’t think that regulatory risks for Chinese companies are over,” says Moringstar analyst Dave Sekera. “However, after examining the companies under our coverage on a case-by-case basis, we have maintained our fair value estimates, as we do not think further regulatory changes will have a meaningful impact on the long-term intrinsic valuations of these specific companies.”Value to Be Had in PGJThe $236.3 million PGJ is home to 99 stocks, nearly 78% of which hail from the consumer discretionary and communication services sectors. In other words, many PGJ components have been directly ensnared in Beijing’s regulatory drag net.Some silver lining for PGJ could be emerging because regulatory risk for some of the fund’s components could be limited going forward.“For the most part, we do not think that the companies we cover operate in those segments that will face the most onerous additional policy changes. And for those that do, we expect that the impact will be limited,” adds Sekera.Among the U.S.-listed Chinese stocks that currently offer investors favorable risk/reward scenarios, according to Morningstar, are e-commerce giants Alibaba and JD.com. JD.com and Alibaba are PGJ’s largest and fifth-largest holdings, respectively, combining for over 18% of the Invesco fund’s weight.Those companies have been front and center in the regulatory crackdown because Beijing believes that they have anti-competitive practices, limiting sellers to a single platform. However, the companies appear willing to allay those concerns and claim to be open to more competitive practices. If they make good on that talk, that could go a long way toward getting regulators off their backs and restoring investor confidence.Other Chinese stocks appearing on the Morningstar undervalued list include Baidu (NASDAQ:BIDU), NetEase (NASDAQ:NTES), and Trip.com (NASDAQ:TRIP). That trio combines for more than 15% of PGJ’s roster.For more news, information, and strategy, visit the Nasdaq Portfolio Solutions Channel.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.